Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 April 2019 : Clinical Research  

High-Mobility Group Box 1 (HMGB1) Promotes Angiogenesis and Tumor Migration by Regulating Hypoxia-Inducible Factor 1 (HIF-1α) Expression via the Phosphatidylinositol 3-Kinase (PI3K)/AKT Signaling Pathway in Breast Cancer Cells

Honger He1AC, Xingmu Wang2BCF, Jianjun Chen2EFG, Liping Sun3AG, Honggang Sun2DE, Kejie Xie2BCD*

DOI: 10.12659/MSM.915690

Med Sci Monit 2019; 25:2352-2360

Abstract

BACKGROUND: High-mobility group box 1 (HMGB1) is an essential contributor towards initiation and progression of many kinds of cancers. Nevertheless, our understanding of the molecular etiology of HMGB1-modulated vasculogenesis, as well as invasion, of breast cancer is poor. This study explored HMGB1 expression in breast cancer and its role in the development and spread of malignancy.

MATERIAL AND METHODS: We enrolled 15 patients with breast cancer who received primary surgery at the Department of Thyroid and Breast Surgery in our hospital. HMGB1 was recorded and analyzed.

RESULTS: Our investigation successfully proves that HMGB1 is upregulated in breast cancer tissues in comparison to the surrounding non-malignant tissues. HMGB1 enhanced vessel formation in breast cancer tissues by regulating hypoxia-inducible factor 1 (HIF-1α), which in turn upregulates the expression of VEGF. Furthermore, HMGB1-mediated upregulation of HIF-1α relies on its ability to stimulate the phosphatidylinositol 3-kinase (PI3K) pathway to reinforce AKT subunit phosphorylation. HMGB1 overexpression reinforces the vasculogenesis in malignancies not only in vivo but also in vitro. Additionally, shRNA knockdown of HMGB1 prohibited the vessel-forming and invasive capabilities, downregulated VEGF and HIF-1α, and suppressed AKT phosphorylation in breast cancer cells. Most importantly, PI3K/AKT axis suppression eliminated the effect of HMGB1-modulated vascularization and invasion in breast cancer cells.

CONCLUSIONS: Our research indicates that HMGB1 serves as a crucial regulator of malignant cell-modulated vessel formation and is involved in the development of malignancy. Our findings indicate that HMGB1 is a promising target for breast cancer treatment.

Keywords: Angiogenesis Inhibitors, HMGB1 Protein, Breast Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, phosphatidylinositol 3-kinase, Phosphorylation, transcriptional activation

Add Comment 0 Comments

Editorial

01 March 2025 : Editorial  

Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials

Dinah V. Parums

DOI: 10.12659/MSM.948672

Med Sci Monit 2025; 31:e948672

0:00

In Press

Clinical Research  

Impact of Nurse-Led Versus Surgeon-Led Preoperative Counseling and Follow-Up on Postoperative Outcomes in P...

Med Sci Monit In Press; DOI: 10.12659/MSM.945597  

0:00

Clinical Research  

Evaluation of Attitudes to Learning Doctor-Patient Communication Skills in 427 Postgraduate Doctors Using t...

Med Sci Monit In Press; DOI: 10.12659/MSM.947276  

0:00

Clinical Research  

Exploring the Association Between Serum Neurogranin, Nardilysin, and Ischemic Stroke: A Case-Control Study ...

Med Sci Monit In Press; DOI: 10.12659/MSM.947703  

0:00

Clinical Research  

Comparative Analysis of Laser Therapies for Striae Distensae: Fractional CO₂ vs Combined Q-Switch Nd:YAG

Med Sci Monit In Press; DOI: 10.12659/MSM.947464  

Most Viewed Current Articles

17 Jan 2024 : Review article   7,036,157

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   702,298

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   27,491

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   21,680

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750